Asia
Yabao Pharmaceutical Subsidiary Secures Chinese Regulatory Approval for High Cholesterol Tablets
China's drug regulator granted Yabao Pharmaceutical's (SHA:600351) Beijing subsidiary a drug registration certificate for its ezetimibe tablets, according to a Saturday filing with the Shanghai bourse.Beijing Yabao Biopharmaceutical's drug treats high cholesterol levels by absorbing cholesterol in the intestine, the pharmaceutical company said in its filing.
SHA:600351